🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

444 results for “Ology” Clear

  1. BBP-398, CETUXIMAB, ADAGRASIB

    Bristol-Myers Squibb / Pfizer EEIG

    Oncology, NSCLC and CRC

    phase 2 small molecule active

    1 trial

  2. BGJ398 (infigratinib)

    BridgeBio Oncology Therapeutics

    Advanced Cholangiocarcinoma

    phase 2 small molecule terminated

    1 trial

  3. BRII-179

    Vir Biotechnology

    For Treatment of Chronic Hepatitis B Virus Infection

    phase 2 mab active

    1 trial

  4. BRII-835 (VIR-2218)

    Vir Biotechnology

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  5. Bamlanivimab

    Vir Biotechnology

    COVID-19

    phase 2 small molecule completed

    1 trial

  6. Bemarituzumab

    Amgen Technology (Ireland) UC

    Solid tumours

    phase 2 small molecule active

    1 trial

  7. Blinatumomab SC2

    Amgen Technology (Ireland) UC

    Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B-Cell Precursor Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  8. CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coat

    Fondazione Telethon ETS

    bladder carcinoma of urothelial and non-urothelial histology

    phase 2 small molecule active

    1 trial

  9. CG0070

    CG Oncology

    Bladder Cancer

    phase 2 mab completed

    1 trial

  10. CG0070

    CG Oncology

    Non Muscle Invasive Bladder Cancer

    phase 2 mab completed

    1 trial

  11. CYCLOPHOSPHAMIDE MONOHYDRATE, BORTEZOMIB, ISATUXIMAB, LENALIDOMIDE, DEXAMETHASONE, DEXAMETHASONE

    Ology Bioservices Ireland LTD

    Newly diagnosed patients with multiple myeloma and severe renal impairment

    phase 2 small molecule active

    1 trial

  12. Capecitabine

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule active

    1 trial

  13. Casdozokitug

    Coherus Oncology

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  14. Cisplatino Accord Healthcare Italia 1 mg/ml concentrato per soluzione per infusione, DOXORUBICINA ACCORD HEALTHCARE ITALIA 2 mg/ml concentrato per soluzione per infusione

    Sana Biotechnology

    Pleural carcinosis

    phase 2 small molecule active

    1 trial

  15. Colonoscopy with enhanced dye

    Cardiff Oncology

    Colorectal Cancer

    phase 2 other completed

    1 trial

  16. Cretostimogene Grenadenorepvec

    CG Oncology

    High-Risk Non-Muscle-Invasive Bladder Cancer

    phase 2 small molecule active

    1 trial

  17. Cytarabine

    Kura Oncology

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  18. DEFLAN 22,75 mg/ml gocce orali, sospensione

    Sana Biotechnology

    Laminopathies

    phase 2 small molecule active

    1 trial

  19. DEXAMETHASONE, CYCLOPHOSPHAMIDE, VINCRISTINE SULFATE, METHOTREXATE, LEVETIRACETAM, Blinatumomab SC2, Blinatumomab SC1, CYTARABINE

    Amgen Technology (Ireland) UC

    Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL,

    phase 2 small molecule active

    1 trial

  20. DEXAMETHASONE, DEXAMETHASONE, LENALIDOMIDE, DARATUMUMAB

    Ology Bioservices Ireland LTD

    newly diagnosed multiple myeloma

    phase 2 small molecule active

    1 trial

  21. DEXAMETHASONE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, DEXAMETHASONE, LENALIDOMIDE, LENALIDOMIDE

    Ology Bioservices Ireland LTD

    Newly diagnosed multiple myeloma

    phase 2 small molecule active

    1 trial

  22. DS-8201a

    AstraZeneca AB

    Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology

    phase 2 small molecule active

    1 trial

  23. DT-DEC01

    Ology Bioservices Ireland LTD

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  24. Dexamethasone

    Kura Oncology

    Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources